Bayer using Accenture’s AI tool to accelerate drug development

By Vassia Barba

- Last updated on GMT

(Image: Getty/ipopba)
(Image: Getty/ipopba)

Related tags Accenture Data management Clinical data Bayer

Bayer collaborates with Accenture on the Intient clinical platform, which integrates internal and external clinical data to accelerate drug development insights.

Accenture Life Sciences, a technology consulting firm, announced that its artificial intelligence​ (AI) clinical data collection and management tool, Intient, is being used by Bayer.

The platform, which went live at Bayer earlier this year, uses cloud-based technology developed by Oracle to enable the collection of internal and external clinical data​ into a single data management and storage platform.

As a result, Intient has the potential to create actionable insights to accelerate drug development and improve patient outcomes.

Under the collaboration agreement between Bayer and Accenture, the former company has also joined the Life Sciences Cloud Coalition​, a group of businesses built by Accenture and Oracle, to link biopharmaceutical companies willing to share their clinical data.

A spokesperson for Accenture told us “With the addition of Bayer, we have already seen a resounding commitment to collaboration with their peers in industry.”

“Bayer brings a global, patient-centric approach to their clinical development processes and have been transparent in their sharing of processes and best practices,”​ the spokesperson added.

Members of the Life Sciences Cloud Coalition include Pfizer, Eli Lilly, Bayer, Merck, Novo Nordisk and GlaxoSmithKline.

The aim of the coalition, according to Accenture, is to enable ‘pre-competitive’ collaboration between companies and support quick and cost-effective advancement of clinical development.

“The future of R&D is bright when leading organizations come together to solve for patients’ greatest needs,”​ commented Mike Stapleton, a managing director in Accenture’s Life Sciences practice.

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 13-Feb-2023 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Related suppliers

Follow us


View more